Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 3/20 | 0.42 |
| ▸ | ICMT | O60725 | 1/20 | 0.41 |
| ▸ | ALB | P02768 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16491449 | 1.00 | DNM1 (0.48) | DNM1NPC1JAK2RAB9APAX8 | |
| SCHEMBL16491475 | 1.00 | DNM1 (0.48) | DNM1NPC1JAK2RAB9APAX8 | |
| SCHEMBL16491473 | 1.00 | DNM1 (0.48) | DNM1NPC1JAK2RAB9APAX8 | |
| SCHEMBL17151053 | 0.93 | CNR2 (0.47) | SIGMAR1CNR2 | |
| SCHEMBL11522611 | 0.93 | NPC1 (0.51) | NPC1JAK2RAB9APAX8SIGMAR1 | |
| SCHEMBL25224466 | 0.91 | NPC1 (0.53) | NPC1JAK2RAB9APAX8SIGMAR1 | |
| SCHEMBL25270420 | 0.91 | NPC1 (0.53) | NPC1JAK2RAB9APAX8SIGMAR1 | |
| SCHEMBL25230044 | 0.91 | NPC1 (0.53) | NPC1JAK2RAB9APAX8SIGMAR1 | |
| SCHEMBL25277336 | 0.91 | NPC1 (0.53) | NPC1JAK2RAB9APAX8SIGMAR1 | |
| SCHEMBL25276956 | 0.91 | NPC1 (0.53) | NPC1JAK2RAB9APAX8SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9394253-B2 | Kinase protein binding inhibitors | HEALTH RESEARCH, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150051245-A1 | KINASE PROTEIN BINDING INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051245-A1 | KINASE PROTEIN BINDING INHIBITORS | PACSIN2, PRKCH, CKS1B | DNM1 2204/4885NPC1 2117/4885JAK2 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.